Form 4: Director James M. Daly Increases Stake in Cytokinetics

Director James M. Daly acquired 191 shares of Cytokinetics common stock as part of the company's Director Equity in Lieu of Cash Retainer Program.

Summary

• Director James M. Daly acquired 191 shares of Cytokinetics (CYTK) common stock on April 15, 2026.
• The shares were acquired at a price of $65.37 per share.
• The acquisition was made through the company's Director Equity in Lieu of Cash Retainer Program.
• Following this transaction, Mr. Daly holds a total of 388 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing reflecting standard director compensation practices.

Positives

• Director demonstrates alignment with shareholders by opting to receive equity in lieu of cash compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine Form 4 disclosure regarding director compensation.

Industry Context

StockSavvy.ai notes that director equity-in-lieu-of-cash programs are standard corporate governance practices designed to align board member interests with long-term shareholder value.

Comparison to Industry Standards

• The use of equity-based compensation for directors is a common practice among mid-cap and large-cap biotechnology firms to preserve cash for R&D activities.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation adjustment.

Next Steps

• None.

Key Dates

Keywords

Cytokinetics, CYTK, Insider Trading, Director Compensation, Equity Retainer